Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glatiramer acetate (Copaxone).

D A Francis1

  • 1Queen Elizabeth Neuroscience Centre, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK.

International Journal of Clinical Practice
|August 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gendered nature of South African teachers' discourse on sex education.

Health education research·2014
Same author

Association between the endogenous retrovirus HRES-1 and multiple sclerosis in the United Kingdom--evidence of genetically different disease subsets?

Disease markers·2001
Same author

CTLA4 in multiple sclerosis. Lack of genetic association in a European Caucasian population but evidence of interaction with HLA-DR2 among Shanghai Chinese.

Journal of the neurological sciences·2001
Same author

Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways.

The EMBO journal·2000
Same author

Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells.

Journal of virology·2000
Same author

The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.

Journal of the neurological sciences·2000
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Glatiramer acetate (GA) is a synthetic peptide treatment that modifies multiple sclerosis (MS) by inducing suppresser T-cells and reducing relapses. It offers similar efficacy to interferon-beta but with better tolerability and fewer side effects.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Current MS treatments aim to modify disease progression and manage symptoms.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Glatiramer Acetate (GA) as a disease-modifying therapy for Multiple Sclerosis (MS).
  • To compare GA's effectiveness and side-effect profile with Interferon-beta (IFN-beta).

Main Methods:

  • Review of laboratory studies on experimental allergic encephalomyelitis (animal model for MS).
  • Analysis of controlled clinical trials assessing GA's impact on MS relapse rates and disability.
  • Comparison of GA's mechanism of action with that of IFN-beta.

Main Results:

Related Experiment Videos

  • Glatiramer acetate (GA) prevents/modifies experimental allergic encephalomyelitis in animal models.
  • GA reduces relapse rates and resultant disability in patients with MS.
  • GA demonstrates comparable efficacy to IFN-beta but with a more favorable side-effect profile and better patient tolerability.

Conclusions:

  • Glatiramer acetate (GA) is an effective disease-modifying treatment for MS, justifying its role as a first-line therapy option.
  • GA's distinct mechanism of action provides an alternative for patients experiencing waning efficacy or side effects from IFN-beta.